Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

If you are located in the EEAEuropean Economic Area, the United Kingdom, or Switzerland, you can change your settings at any time by clicking Manage Cookies in the footer of our website.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Lumit® SARS-CoV-2 Spike RBD: hACE2 Immunoassay

new-kit-box
customize-this-small

No-Wash Detection of Spike (RBD) and Human ACE2 Interaction

Please Enquire
This product is discontinued
This product is available under our Early Access program - Learn More
This product is available under our Catalog (FT) program - Learn More
Lumit® SARS-CoV-2 Spike RBD: hACE2 Immunoassay

Scalable Assay to Monitor Viral:ACE2 Interaction

The Lumit® SARS-CoV-2 Spike RBD: hACE2 Immunoassay* is a homogeneous bioluminescent assay that measures levels of interaction between SARS-CoV-2 Spike protein receptor binding domain (RBD) and human angiotensin-converting enzyme 2 (ACE2).

NanoBiT® subunits are conjugated to a pair of secondary antibodies against two different species (anti-rabbit and anti-mouse antibodies). To detect interaction between RBD and ACE2, a rabbit Fc domain-tagged RBD and a mouse Fc domain-tagged ACE2 are mixed together with SmBiT- and LgBiT-conjugated secondary antibodies (Lumit® Anti-Mouse Ab-LgBiT and Lumit® Anti-Rabbit Ab-SmBiT). Interaction of RBD and ACE2, along with binding of the Lumit® secondary antibodies to their corresponding epitopes on the Fc-domains, brings NanoBiT® subunits into proximity to form an active NanoLuc® luciferase enzyme that generates light in proportion to the amount of target protein.

Mutant rabbit Fc domain-tagged Spike RBD proteins are now available to monitor how these mutations influence the effectiveness of potential neutralizing antibodies (purified or in patient samples), peptides or small molecule inhibitors.

Learn more about the Lumit® SARS-CoV-2 Spike RBD: hACE2 Immunoassay in the 30-minute webinar "Screening for SARS-CoV-2 Spike Protein Interactions".

View Webinar

*For Research Use Only. Not for Use in Diagnostic Procedures.

Assay Principle

SARS-CoV 2 Spike RBD: hACE2 Immunoassay principle

Lumit® SARS-CoV-2 Spike RBD: hACE2 Immunoassay principle. Detection of RBD-rabbit Fc:hACE2-mouse Fc interaction is performed by Lumit® secondary antibodies (Lumit® Anti-Mouse Ab-LgBiT and Lumit® Anti-Rabbit Ab-SmBiT). Panel A. Binding of the antibodies to the proteins promotes the reconstitution of NanoLuc® luciferase, generating bioluminescence. Panel B. The presence of a molecule that disrupts the RBD-hACE2 interaction reduces the bioluminescent signal.

Surrogate Neutralization Assay

Neutralization of RBD ACE2 Interaction

Detection of neutralizing effects of patient serum samples with the Lumit® SARS-CoV-2 Spike RBD: hACE2 Immunoassay. PCR-positive (n = 40) and pre-pandemic (n = 43) patient serum samples were incubated with 1.5nM of each of SARS-CoV-2 RBD (Rabbit Fc), hACE2 (Mouse Fc) and Lumit® Antibody Mix. After a 1 hour incubation at 23°C, 12.5μl Lumit® Detection Reagent was added, followed by incubation at room temperature for 30 minutes. Luminescence was recorded using a GloMax® Discover Microplate Luminometer (Cat.# GM3000). Net luminescence values of all samples were converted to percentage PPI activity using the “Lumit Reagents Only” and “Pre-COVID19 negative serum” controls as 0% and 100%, respectively. Sample percent neutralization was calculated as [100 – % PPI activity]. The dotted line represents the cutoff of at 30% neutralization/inhibition.

Evaluation of Antibody Neutralization Levels on Major SARS-CoV-2 RBD Mutant Variants

17815ma

Antibody titrations with wild-type RBD-Fc and variants containing the E484K, K417N, K417T and N501Y mutations. Monoclonal anti-SARS-CoV-2 RBD antibodies were serially diluted and incubated with wild-type and the major mutant variants of RBD-Fc for 30 minutes prior to the addition of hACE2-Fc and Lumit® antibodies. Different antibody selectivity patterns were observed with RBD-Fc mutants. Mutations can confer some antibody inhibition escape to RBD. Some antibodies can still inhibit the mutant RBD interaction with ACE2 similar to WT.

See More Data: This peer-reviewed paper, published in Nature Communications Biology, shows how the Lumt™ SARS-CoV-2 Spike RBD: hACE2 Immunoassay assay can be used to discover novel inhibitors that block the binding of SARS-CoV-2 to human ACE2, and to study how mutations in the SARS-CoV-2 spike protein alter its apparent affinity for human ACE2. The paper also details studies where the assay was used to detect the presence of neutralizing antibodies from COVID-19-positive samples and samples from vaccinated individuals. 

Read the Paper
scientific-reports-paper-image

Let's find the product that meets your needs.

Talk to a Scientist

scientist-uk-angus

Angus

UK
Choose your country

Americas

Brazil
/
Canada
/
United States
/

Pacific Asia

Australia
China
/
India
Japan
/
Korea, Republic of
/
Singapore

Europe

Austria
/
Belgium
Denmark
(Incl. Faroe Isl. & Greenland)
Estonia
Finland
(Incl. Åland)
France
/
Germany
/
Iceland
Ireland
Italy
/
Luxembourg
Netherlands
Norway
(Incl. Svalbard)
Poland
/
Spain
/
Sweden
Switzerland
United Kingdom

Manage Cookies

Necessary Cookies

We use these cookies to ensure our site functions securely and properly; they are necessary for our services to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as logging in, using a shopping cart or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of our services will not work without them. Like the other cookies we use, strictly necessary cookies may be either first-party cookies or third - party cookies.

Preference Cookies

We use these cookies to remember your settings and preferences. For example, we may use these cookies to remember your language preferences.

Performance/Statistics Cookies

We use these cookies to collect information about how you interact with our services and to help us measure and improve them. For example, we may use these cookies to determine if you have interacted with a certain page.

Marketing Cookies

We and our advertising partners use these cookies to deliver advertisements, to make them more relevant and meaningful to you, and to track the efficiency of our advertising campaigns, both on our services and on other websites and social media.

Your Privacy Choices

Our website supports your privacy choices by allowing users in select regions to opt out of specific types of sharing/sales/use of cookies and technologies for Targeted Advertising. Visit our Privacy Policy and Cookie Policy pages to learn more about these topics.

Targeted Advertising

Deselect this checkbox to disable cookies related to targeted advertising in your Promega experience. These advertising cookies will no longer be set for this browser and device.

Note: These settings are based on necessary cookies that are placed on your device, and if those cookies are cleared or you access the website from another browser or device, advertising cookies might be reset by default in the future, from which you can opt-out.